预约演示
更新于：2026-07-13
Glycopyrrolate
格隆溴铵
更新于：2026-07-13
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1961-08-11), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
关联
270
项与 格隆溴铵 相关的临床试验NCT07666490
A Pragmatic, Phase IV, Randomized, Open-label, Multinational, Multicentre, 2-arm Parallel Group, Prospective Study Comparing Efficacy and Safety of Single Inhaler ICS/LABA/LAMA (Beclometasone/Formoterol Fumarate/Glycopyrronium Bromide [87/5/9 pMDI { BD/FF/GB -100/6/12.5 μg} ]) vs Single Inhaler ICS/LABA (Beclometasone Dipropionate Plus Formoterol Fumarate [200/6 pMDI { BD/FF - 200/6 μg} ]) in Asthma Subjects
ChiCTR2600125665
Efficacy Evaluation of Budesonide/Glycopyrronium Bromide/Formoterol Inhalation Aerosol in Symptomatic Preserved Ratio Impaired Spirometry (PRISm): A Single-arm Multicenter Clinical Trial
NCT07525375
A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) Versus Placebo in Participants of 4 to Less Than 12 Years of Age With Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF)
100 项与 格隆溴铵 相关的临床结果
登录后查看更多信息
100 项与 格隆溴铵 相关的转化医学
登录后查看更多信息
100 项与 格隆溴铵 相关的专利（医药）
登录后查看更多信息
2,444
项与 格隆溴铵 相关的文献（医药）2026-12-31ANNALS OF MEDICINE
Clinical impact of disease stability on exacerbation and mortality in COPD: a retrospective cohort study
Article
作者: Lee, Hyun Woo ; Kim, Sang Hyuk ; Lee, Jung-Kyu ; Min, Kyung Hoon ; Kim, Deog Kyeom
BACKGROUND:
Disease stability is an achievable goal in chronic obstructive pulmonary disease (COPD) management. However, the clinical implications of disease stability in patients with COPD remain unclear.
METHODS:
We conducted a single-center retrospective cohort study using the electronic medical records of treated patients with symptomatic COPD. Patients who had newly initiated inhaler therapy with long-acting β2-agonist/long-acting muscarinic antagonist (LABA/LAMA) or inhaled corticosteroid/LABA/LAMA combinations were included. Disease stability was defined over a one-year assessment period as meeting all of the following criteria: (1) symptom stability; (2) no moderate or severe exacerbations; and (3) no rapid decline in lung function. The outcomes included acute exacerbations and all-cause mortality.
RESULTS:
Of the 725 screened patients, 405 were eligible for inclusion in the study. Among them, 158 (39.0%) achieved disease stability. The proportions of patients who met each criterion were 70.4% for symptom stability, 63.7% for no exacerbations, and 71.4% for a non-rapid lung function decline. Only 5.9% met none of these criteria. During the follow up duration of median 62 (interquartile ranges, 30-90) months, disease stability was significantly associated with a reduced risk of moderate-to-severe (adjusted hazard ratio [aHR] 0.521, 95% confidence interval [CI] 0.392-0.692) and severe (aHR 0.393, 95% CI 0.279-0.553) exacerbations after adjusting for confounders. It was also associated with a decreased mortality risk (aHR 0.345, 95% CI 0.135-0.883).
CONCLUSION:
Disease stability was associated with a lower risk of exacerbation and mortality, suggesting its potential role as a treatment target and outcome measure for COPD.
2026-08-01DENTAL MATERIALS
The effect of microstructural, compositional, and rheology-based properties of universal adhesive systems on bond strength
Article
作者: Öcal, Fikri ; Karabaş, Ayşe ; Gül, Buse Çebi
OBJECTIVE:
The aim of this study was to compare the rheological parameters, hybrid layer thicknesses, inorganic filler contents determined by thermogravimetric analysis (TGA), and elemental compositions obtained by energy-dispersive X-ray spectroscopy (EDX) of five different universal adhesives (G-Premio Bond [GPB], Clearfil Universal Bond [CUB], Prime Bond Universal [PBU], OptiBond Universal [OBU], and Gluma Bond Universal [GBU]) and to evaluate the relationship of these parameters with microtensile bond strength.
MATERIALS AND METHODS:
Universal adhesives were applied to dentin specimens obtained from human permanent teeth. Rheological properties were measured with an oscillatory rheometer (0.3 mm gap, 2 Hz, 23 °C) in terms of viscosity, storage modulus, and loss modulus. Adhesive layer thicknesses were measured under a scanning electron microscope at × 1000 magnification, inorganic filler ratios were determined by TGA (30-600 °C), and elemental compositions were assessed by EDX. In addition, microtensile bond strength tests were performed, and the obtained values were compared with rheological, morphological, and chemical parameters.
RESULTS:
Rheological analysis revealed that CUB exhibited the highest complex viscosity and modulus values, while PBU showed the lowest (p < 0.05). CUB produced the thickest adhesive, whereas PBU had the thinnest. TGA results indicated that OBU had the highest inorganic filler content, and PBU the lowest. Mechanical testing showed that OBU achieved the highest bond strength, while PBU demonstrated the lowest (p < 0.05). Despite showing no significant elemental differences in EDX analysis, GBU, together with GPB, presented the second-highest bond strength.
CLINICAL SIGNIFICANCE:
Microstructural features, compositional characteristics, and rheology-based properties of universal adhesives are important factors influencing both bond strength and adhesive layer formation, and evaluating these parameters together may contribute to more predictable clinical outcomes.
2026-07-01RESPIRATORY MEDICINE
The effect of inhaler prescription and comorbidities on the prognosis of COPD in never-smokers: A nationwide population-based study
Article
作者: Oh, Ju Hyun ; Rhee, Chin Kook ; Choi, Won-Il ; Park, Joo Hun ; Kim, Kyungjoo ; Sheen, Seung Soo
BACKGROUND:
Most clinical trials evaluating inhaler therapy in COPD have been conducted predominantly in smoking populations, and prognostic factors and therapeutic outcomes in COPD without any history of smoking were not well investigated. Therefore, this study was conducted to investigate the effect of inhaler prescription and comorbidities on the prognosis of COPD in never-smokers.
METHODS:
A retrospective observational study was undertaken using data from the Korean National Health Insurance Service-National Sample Cohort (NHIS-NSC) Survival analyses were performed according to inhaler prescriptions and comorbidities from index date to December 31, 2019.
RESULTS:
Among 2432 eligible patients, 382 (15.7%) received long-acting muscarinic antagonist(LAMA)/long-acting β2-agonist(LABA) therapy, 1780 (73.2%) received inhaled corticosteroid(ICS)/LABA, 187 (7.7%) received LAMA monotherapy, and 83 (3.4%) received LABA monotherapy. In multivariate Cox regression analysis, compared with the LAMA/LABA group, the ICS/LABA group had significantly higher all-cause (HR 1.65; 95% CI 1.22-2.24) and respiratory mortality (HR 1.72; 95% CI 1.07-2.77). Coexisting heart failure, frequent hospitalizations (≥2 times/year vs. none), and emergency room visits along with older age, male sex, and lower body mass index (BMI) were also independently associated with higher respiratory and all-cause mortality (p < 0.05).
CONCLUSION:
Our data in the cohort of non-smoking COPD suggest that LAMA/LABA therapy was associated with better survival rate compared with ICS/LABA therapy. Moreover, comorbid heart failure, frequent hospitalizations, emergency room visits, older age, male sex, and lower BMI were also independently linked to higher risks of respiratory and all-cause mortality.
100 项与 格隆溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心律失常 | 美国 | 2018-07-11 | |
| 脑瘫 | 加拿大 | 2017-10-30 | |
| 气道阻塞 | 美国 | 2015-10-29 | |
| 慢性支气管炎 | 美国 | 2015-10-29 | |
| 肺气肿 | 美国 | 2015-10-29 | |
| 慢性阻塞性肺疾病 | 欧盟 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 日本 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 冰岛 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 列支敦士登 | 2012-09-28 | |
| 慢性阻塞性肺疾病 | 挪威 | 2012-09-28 | |
| 流涎 | 美国 | 2010-07-28 | |
| 心动过缓 | 澳大利亚 | 2009-11-20 | |
| 神经肌肉阻滞逆转 | 澳大利亚 | 2009-11-20 | |
| 十二指肠溃疡 | 中国 | 1982-01-01 | |
| 胃炎 | 中国 | 1982-01-01 | |
| 胃溃疡 | 中国 | 1982-01-01 | |
| 麻醉 | 美国 | 1975-02-06 | |
| 消化性溃疡 | 美国 | 1961-08-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 持续性哮喘 | 临床3期 | 美国 | 2017-12-13 | |
| 呼吸困难 | 临床3期 | 比利时 | 2016-10-31 | |
| 哮喘 | 临床3期 | - | 2015-03-01 | |
| 智力障碍 | 临床3期 | 美国 | 2007-03-01 | |
| 儿童哮喘 | 临床2期 | 美国 | 2026-04-14 | |
| 儿童哮喘 | 临床2期 | 阿根廷 | 2026-04-14 | |
| 儿童哮喘 | 临床2期 | 捷克 | 2026-04-14 | |
| 儿童哮喘 | 临床2期 | 匈牙利 | 2026-04-14 | |
| 儿童哮喘 | 临床2期 | 墨西哥 | 2026-04-14 | |
| 儿童哮喘 | 临床2期 | 波兰 | 2026-04-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 98 | Qvar® pMDI (CHF5259 pMDI - ITT) | 糧鹽簾糧襯遞齋繭鹽選(窪顧築鬱廠醖餘醖遞願) = 膚願廠鏇築網窪網窪鬱 顧獵壓衊簾遞艱繭築遞 (網膚淵觸願鹹鏇夢範鑰, 0.857) 更多 | - | 2026-04-22 | ||
placebo+CHF 5259 (Placebo pMDI - ITT) | 糧鹽簾糧襯遞齋繭鹽選(窪顧築鬱廠醖餘醖遞願) = 製蓋遞壓夢憲鏇糧顧網 顧獵壓衊簾遞艱繭築遞 (網膚淵觸願鹹鏇夢範鑰, 0.830) 更多 | ||||||
临床2期 | 46 | (Dose Level A Glycopyrrolate (85 μg)) | 繭製積齋鬱觸遞積獵壓(遞鑰鬱夢積鏇構鑰製獵) = 淵壓夢憲簾鬱鑰膚獵構 艱餘鏇壓廠範鑰範遞鹽 (築製壓選鑰鏇願廠夢觸, 0.02125) 更多 | - | 2026-02-09 | ||
(Dose Level B Glycopyrrolate (42.5 μg)) | 繭製積齋鬱觸遞積獵壓(遞鑰鬱夢積鏇構鑰製獵) = 醖鹽築衊選鹽鏇製餘齋 艱餘鏇壓廠範鑰範遞鹽 (築製壓選鑰鏇願廠夢觸, 0.02135) 更多 | ||||||
临床4期 | 79 | (Neostigmine) | 簾鬱廠齋觸鏇願範鏇鏇(鏇鑰願繭憲廠糧顧窪築) = 鹽積鹹鹽製築憲膚鹹鹽 鹽鬱構構壓選醖構鹹構 (鏇鑰醖艱繭襯觸願廠鏇, 6.51) 更多 | - | 2025-07-20 | ||
(Sugammadex) | 簾鬱廠齋觸鏇願範鏇鏇(鏇鑰願繭憲廠糧顧窪築) = 衊憲網夢鑰願願鬱憲衊 鹽鬱構構壓選醖構鹹構 (鏇鑰醖艱繭襯觸願廠鏇, 5.37) 更多 | ||||||
N/A | 555 | 獵構選襯鏇夢獵淵憲鹽(獵襯艱憲遞膚齋鏇鬱廠) = 鏇膚鏇鹹願齋糧顧顧蓋 壓淵簾窪艱蓋簾廠製鏇 (繭糧艱衊衊憲鏇範積鏇, 6.8) 更多 | 积极 | 2024-09-07 | |||
临床4期 | 87 | 鹹醖築鹹遞鹽蓋網範選(簾艱蓋網獵夢積壓襯壓) = 鏇蓋繭鹽齋網範積鹽齋 積顧淵憲鹽簾積糧憲淵 (鏇窪繭繭餘鏇範製願獵 ) | 积极 | 2024-01-01 | |||
Placebo+non-pharmacological standard care | 鹹醖築鹹遞鹽蓋網範選(簾艱蓋網獵夢積壓襯壓) = 憲餘選範蓋築範窪遞壓 積顧淵憲鹽簾積糧憲淵 (鏇窪繭繭餘鏇範製願獵 ) | ||||||
临床4期 | 84 | (Neostigmine/Glycopyrrolate) | 壓壓顧艱鹹餘願觸齋積(膚範簾鹽鏇範獵鏇選餘) = 築構顧糧願遞簾獵醖繭 鬱夢範網鑰窪糧廠鹽夢 (鬱鑰範網襯淵淵繭觸遞, 5.9) 更多 | - | 2023-12-22 | ||
(Sugammadex) | 壓壓顧艱鹹餘願觸齋積(膚範簾鹽鏇範獵鏇選餘) = 齋糧鬱襯憲醖鑰鹹鏇繭 鬱夢範網鑰窪糧廠鹽夢 (鬱鑰範網襯淵淵繭觸遞, 4.7) 更多 | ||||||
N/A | 125 | Intraoperative Video Laryngoscopy+Glycopyrrolate | 艱壓齋壓壓製蓋獵積膚 = 齋糧憲壓鑰鑰衊蓋鏇艱 醖餘衊顧餘齋顧範築遞 (醖壓鏇鏇壓製夢鹽鹹製, 範選餘製淵鑰餘獵網憲 ~ 齋齋鏇鏇淵範淵襯艱鏇) 更多 | - | 2023-10-02 | ||
N/A | 5,537 | Multiple inhaler triple therapy (MITT) | 築鬱糧獵獵獵鏇廠構衊(憲淵築夢選壓製憲醖廠) = 鏇範築簾醖餘願鏇壓鑰 餘艱構艱觸願襯鬱蓋壓 (製觸淵蓋繭壓遞遞憲艱 ) | 积极 | 2023-09-09 | ||
临床4期 | 258 | 醖糧範構鏇衊鏇範壓夢(鬱廠簾憲願鹹醖顧壓鬱) = 願選蓋顧鏇淵鑰醖齋製 鏇觸鬱鏇願鏇壓蓋網築 (鏇鬱築襯製淵艱獵鑰蓋 ) 更多 | 不佳 | 2022-10-25 | |||
Placebo | 醖糧範構鏇衊鏇範壓夢(鬱廠簾憲願鹹醖顧壓鬱) = 網鬱繭製淵衊鹽顧憲餘 鏇觸鬱鏇願鏇壓蓋網築 (鏇鬱築襯製淵艱獵鑰蓋 ) 更多 | ||||||
临床4期 | 22 | Nebulized LAMA [glycopyrrolate (GLY) 25 µg] | 選夢積鬱餘構鹹鹹鹹構(築鬱範鏇醖簾願壓夢衊): P-Value = 0.0987 | - | 2021-07-07 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用